What are the clinical trial results of Capisetin Tablets/Capositinib worth paying attention to?

Capivasertib (Capivasertib), as an oral AKT kinase inhibitor, has shown great potential in the field of tumor treatment, especially in the precision treatment of breast cancer. The AKT pathway plays a key role in cell proliferation, metabolism and survival, and its abnormal activation is closely related to the occurrence, development and drug resistance mechanisms of various tumors. Carpisetin effectively blocks the proliferation and survival of tumor cells by targeting the AKT signaling pathway, and has become a targeted drug that has attracted much attention in recent years. Multiple clinical trials have revealed the safety and efficacy of the drug, laying a solid foundation for its clinical application.

First of all, the application of capicipositi is particularly significant in patients with hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Clinical studies have shown that carpisetin combined with the endocrine therapy drug fulvestrant significantly prolonged the progression-free survival (PFS) and overall response rate of patients. Especially in patients who have previously received endocrine therapy but whose disease has progressed, this combination provides a new treatment option and breaks the bottleneck of single resistance to traditional endocrine therapy. This combination not only targets the core signaling pathways of tumor cells, but also takes into account patient tolerance, greatly improving the therapeutic effect.

In terms of safety, multiple clinical trial results show that carpisetin is well tolerated. Common adverse reactions include fatigue, nausea, rash and mild gastrointestinal reactions, but most are mild to moderate and can be effectively controlled through dose adjustment and symptomatic treatment. The cyclical medication plan, that is, taking it continuously for 4 days and then stopping the medication for 3 days, is designed to balance the efficacy and side effects and protect the patient's quality of life. This program also helps patients better complete the treatment plan and improve medication compliance.

In addition, the role of carpisetin is not limited to breast cancer. It has also shown certain potential in clinical trials of solid tumors such as non-small cell lung cancer (NSCLC) and prostate cancer. Studies have found that for tumor subtypes with abnormal activation of the PI3K/AKT/mTOR pathway, carpisetine can effectively inhibit tumor growth and delay disease progression. Some trials are evaluating the combined use of carpisetin with immune checkpoint inhibitors and chemotherapy drugs, with the hope of further improving patient treatment benefits through multi-target synergy.

Of note is the role of carpisetin in overcoming resistance mechanisms. Tumor cells often become resistant to endocrine therapy or other targeted drugs, andActivation of the AKT signaling pathway is one of the main drug resistance pathways. By precisely inhibiting AKT, carpisetin can reverse or delay drug resistance, bringing new treatment hope to advanced patients. Current research is also exploring combination strategies with other signaling pathway inhibitors in order to comprehensively cover the complex molecular mechanisms of tumors.

Although carpisetin shows good promise, clinical application still requires attention to some challenges. For example, there are individual differences in the response of different patients to drugs, so how to accurately screen suitable patient groups becomes key. In addition, the management of possible side effects and drug resistance issues caused by long-term medication also require continued attention and research.

Reference materials:https://www.drugs.com/mtm/capivasertib.html